Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04746729

Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy

The goal of the HARMONIC-RT study is to evaluate late health and social outcomes of contemporary techniques of external beam radiotherapy in paediatric patients, based on the setting-up of a European, long-term registry complemented by a biobank.

Recruiting

Interested in participating?

Request Info

Key information

Age range

Up to 22 year

Sex eligibility

All sexes

Study type

Observational

Primary location

KU Leuven, Leuven, Belgium

Loading trial locations.

About this study

Specific objectives:

  • To develop the infrastructure and instruments for setting-up a European, long-term registry of paediatric patients treated with contemporary techniques of modern external radiotherapy;
  • To assess the incidence and severity of late health outcomes, primarily endocrine dysfunctions, cardiovascular toxicities, neurovascular damages, and subsequent primary neoplasms, in relation to the dose-volume distribution to non-targeted organs and tissues, radiation delivery technique and beam quality factors, and potential modifying factors (i.e. age at exposure, genetic predispositions, comorbidities, and systemic treatments including chemotherapy, targeted therapy, immunotherapy and hormonal drugs) that may underlie differences in individual susceptibility for these outcomes ;
  • To assess societal aspects of advances in radiotherapy, primarily health-related quality of life and academic achievement, in paediatric patients treated with modern external radiotherapy techniques.

Secondary scientific objectives:

  • To assess multidimensional fatigue in paediatric patients treated with modern external radiotherapy techniques, and identify clinical and therapeutic determinants of fatigue;
  • To improve estimation of patient-specific doses to the whole body and non-targeted organs and substructures from different radiotherapy delivery techniques;
  • To investigate radiation-induced cellular responses and biological mechanisms related to the occurrence of vascular diseases and subsequent primary neoplasms in samples of blood and saliva ; to identify biomarkers of susceptibility and health effects ; to evaluate differences in disease biomarkers in relation to the radiation delivery technique and beam quality factors ; to explore the relevance of the use of saliva as a biosampling method for paediatric cohorts regarding feasibility and the quality and reproducibility for different measured biomarkers.

Secondary strategic objectives:

  • To promote sustained collaborative research activities for improvement of patient care, and inform health care providers and policy makers on the clinical and social impact of advances in radiotherapy in paediatric settings;
  • To serve as a pilot for a future long-term pan-European registry of children and adolescents treated with particle and photon beam therapy, including a biobank of saliva and blood samples collected before and after treatment;
  • To contribute in future collaborative projects with existing cohorts or registries in Europe
  • To contribute in future international research studies on late outcomes of modern radiotherapy techniques for management of paediatric cancers

Funding: The HARMONIC project has received funding from the Euratom research and training programme 2014-2018 under grant agreement No 847707.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Retrospective inclusion of study participants

Inclusion criteria

  • First external beam radiation therapy (EBRT) started in 2000 or after for management of a first primary neoplasm
  • Age under 22 years at the time of first EBRT initiation
  • Radiation treatment plan (first EBRT) stored in DICOM format
  • Usual residency in the country of EBRT to enable a long-term follow-up

Exclusion criteria

  • Patients with poor prognosis (e.g. diffuse pontine glioma or high grade glioma) at first EBRT initiation
  • Prior external or internal radiation therapy
  • Patients who refused to participate in the study

Prospective inclusion of study participants

Inclusion criteria

  • Scheduled first EBRT for management of a first primary neoplasm
  • Age under 22 years at the time of scheduled first EBRT
  • Radiation treatment plan stored in DICOM format
  • Affiliate or beneficiary of health insurance (or any required equivalent as defined in applicable national law)
  • Usual residency in the country of EBRT to enable a long-term follow-up
  • Signed informed consent/assent

Exclusion criteria

  • Patients with poor prognosis (e.g. diffuse pontine glioma or high grade glioma)
  • Prior external or internal radiation therapy;
  • Protected adults (persons under curatorship, tutorship / individuals under guardianship by court order, persons deprived of their liberty)
  • Adult/parent(s)/legal representative(s) who cannot read or understand the informed consent in the applicable language(s) in the country of EBRT

Treatment and study plan

No intervention

Other

No intervention

Primary outcomes

  1. Endocrinopathies

    Time frame: up to 20 years after RT

    Late health outcomes

  2. Cardiovascular diseases

    Time frame: up to 20 years after RT

    Late health outcomes

    • Neurovascular diseases
    • Second and subsequent primary neaoplasms
  3. Neurovascular diseases

    Time frame: up to 20 years after RT

    Late health outcomes

  4. Second and subsequent primary neaoplasms

    Time frame: up to 20 years after RT

    Late health outcomes

  5. Health-related quality of life (physical, emotional, social, and school functioning) assessed by the PedsQL™ core scale (validated questionnaire)

    Time frame: up to 10 years after radiation therapy or attained age 25 years, whichever occurs first

    Late social outcomes

  6. Academic achievement

    Time frame: up to 10 years after radiation therapy or attained age 25 years, whichever occurs first

    Late social outcomes

Secondary outcomes

  1. Dysfunctions in endocrine hormone levels

    Time frame: up to 10 years after radiation therapy

    measured as:

    • insulin-like growth factor-1,
    • anterior pituitary hormones (GH, ACTH, TSH, LH, FSH),
    • thyroid hormones (fT3, fT4),
    • sexual hormones
  2. Changes in blood markers of cardiovascular diseases

    Time frame: up to 10 years after radiation therapy

    measured as blood markers (incl. troponin, BNP, CPK)

  3. Changes in imaging markers of cardiovascular diseases

    Time frame: up to 10 years after radiation therapy

    measured as cardiac echography parameters (incl. ejection fraction, diastolic function)

  4. Changes in imaging markers of neurovascular damages

    Time frame: up to 5 years after radiation therapy

    measured as scoring of large and small vessel damages

  5. Changes in blood/saliva markers of protein activation relating to vascular damages

    Time frame: up to 1 year after radiation therapy

    measured as signal quality of protein activity

  6. Changes in blood/saliva markers of oxidative stress response

    Time frame: up to 1 year after radiation therapy

    measured as markers of oxidative stress (incl. 8-oxo-dG, SOD2, DNA repair enzymes)

  7. Changes in blood/saliva markers of inflammatory response

    Time frame: up to 1 year after radiation therapy

    Inflammatory markers (incl. PTX3, CRP, NF-kB, IL-1 and IL10)

  8. Changes in blood/saliva markers of carcinogenesis

    Time frame: up to 1 year after radiation therapy

    Markers of carcinogenesis (incl. leukocyte telomere length, mitochondrial DNA copy number, circulating microRNA)

  9. Multidimensional fatigue (general, sleep/rest, and cognitive fatigue)

    Time frame: up to 10 years after radiation therapy or attained age 25 years, whichever occurs first

    PedsQL™ multidimensional fatigue scale (validated questionnaire)

  10. Clinical events other than those mentioned as primary outcomes

    Time frame: up to 20 years after radiation therapy

    Late morbidity

  11. All-cause and cause-specific mortality

    Time frame: up to 20 years after radiation therapy

    Late mortality

Study contacts

Contact information is provided by the study sponsor or research team.

Beate Timmermann, MD

CONTACT

[email protected]

+49 201 723 64

Neige Journy, PhD

CONTACT

[email protected]

+33 142 11 54 27

Sponsors and collaborators

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Other Gov

Collaborators

  • Aarhus University Hospital
  • Barcelona Institute for Global Health
  • Centre Francois Baclesse
  • Commissariat A L'energie Atomique
  • Gustave Roussy, Cancer Campus, Grand Paris
  • KU Leuven
  • Luxembourg Institute of Science and Technology
  • National Research Council, Institute of Clinical Physiology, Italy
  • Princess Maxima Center for Pediatric Oncology
  • Stockholm University
  • The West German Proton Therapy Centre, Essen
  • University Hospital, Essen
  • University Medical Center Groningen
  • University of Aarhus
  • University of Zurich

Registry information

Official study title

Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy (HARMONIC-RT)

Acronym: HARMONIC-RT

Important dates

Study start
2021
Primary completion
2040
Study completion
2040
First posted
Feb 10, 2021
Registry last updated
Apr 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.